Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors

BACKGROUND: Clinical responses to EGFR tyrosine kinase inhibitors (TKIs) are restricted to tumors harboring specific activating mutations and even then, not all tyrosine kinase inhibitors provide clinical benefit. All TKIs however, effectively inhibit EGFR phosphorylation regardless of the mutation...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:EBioMedicine
Main Authors: de Wit, Maurice, Gao, Ya, Mercieca, Darlene, de Heer, Iris, Valkenburg, Bart, van Royen, Martin E., Aerts, Joachim, Sillevis Smitt, Peter, French, Pim
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2020
Assuntos:
Research paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7276512/
https://ncbi.nlm.nih.gov/pubmed/32512509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102796
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares